JPM vs NEWT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
NewtekOne presents a classic 'value trap' profile, characterized by a very weak Piotroski F-Score of 2/9 indicating deteriorating fundamental health. While the stock is significantly undervalued relative to its Graham Number ($24.45) and Intrinsic Value ($15.26), this is offset by negative earnings growth (-6.00% YoY) and a high Debt/Equity ratio of 2.07. The strong dividend yield of 6.05% provides a floor, but the lack of growth and poor health metrics prevent a bullish rating. The discrepancy between the deep value metrics and the bearish technical trend suggests the market is pricing in fundamental risks.
Compare Another Pair
Related Comparisons
JPM vs NEWT: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and NewtekOne, Inc. (NEWT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.